Increased digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy

T Hayashi1, Y Ijiri, H Toko

  • 1The Third Division, Department of Medicine, Osaka Medical College, Takatsuki, Osaka, Japan.

European Heart Journal
|February 2, 2000
PubMed

Insights

Digitalis-like immunoreactive substances were elevated in the plasma and heart cells of hypertrophic cardiomyopathy patients. These substances may be linked to pressure overload and affect cardiac cell function.

Area of Science:

  • Cardiology
  • Biochemistry
  • Immunohistochemistry

Background:

  • Digitalis-like immunoreactive substances (DLIS) are implicated in hypertension and heart failure.
  • Limited data exists on DLIS in hypertrophic cardiomyopathy (HCM).

Purpose of the Study:

  • To investigate the presence and significance of DLIS in plasma and myocardial tissue of HCM patients.

Main Methods:

  • Fluorescence polarization immunoassay for plasma DLIS quantification.
  • Immunohistochemical analysis of endomyocardial biopsy specimens using anti-digoxin antibody.
  • Correlation analysis with clinical parameters and ultrastructural localization.

Main Results:

  • Elevated plasma DLIS (>0.2 ng/mL) found in 22.2% of non-obstructive and 38.4% of obstructive HCM patients.
  • DLIS detected heterogeneously in cardiocytes, localized to sarcolemma, T-tubules, and Z-bands.
  • Plasma DLIS correlated with left atrial dimension and cardiac index in non-obstructive HCM; correlated with myocardial DLIS and LV end-diastolic pressure in obstructive HCM.

Conclusions:

  • Increased DLIS in plasma and cardiocytes of HCM patients, potentially due to pressure/volume overload.
  • DLIS may interact with the sarcolemma and be transported intracellularly within cardiocytes.
Abstract

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
645
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
493
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
790
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
805
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
753